ISHITA DRUGS & INDUSTRIES LTD.

Ishita Drugs & Industries Ltd has issued letters to members who have not registered their email addresses, providing a weblink to access the Annual Report for the Financial Year 2025-26 and the Notice of the 33rd Annual General Meeting. This action complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The AGM is scheduled for September 30, 2026. Members are encouraged to update their KYC details and register their email addresses.

Ishita Drugs & Industries Ltd has filed its Annual Report for the Financial Year 2025-26, along with the Notice of its 33rd Annual General Meeting (AGM). The AGM is scheduled to be held on September 30, 2026. The report, submitted to the BSE, complies with SEBI (LODR) Regulations, 2015. Key agenda items include the re-appointment of Mrs. Abha Agrawal as a Non-Executive Non-Independent Director and the approval of related party transactions with Ishita Pharmaceuticals. The company's website will also host the annual report.

Ishita Drugs & Industries Ltd has announced its 33rd Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 11:30 a.m. IST at "Manthan", Hotel Krsna Lila, Gujarat. The company is providing members with the facility for e-voting, which will commence on Sunday, September 27, 2026, at 9:00 a.m. IST and conclude on Tuesday, September 29, 2026, at 5:00 p.m. IST. Members who have not voted electronically can also cast their vote via ballot paper at the meeting. The agenda includes re-appointment of Mrs. Abha Agrawal and approval of related party transactions with Ishita Pharmaceuticals.

Ishita Drugs & Industries Ltd has announced the e-voting period for its 33rd Annual General Meeting (AGM). The e-voting will commence on September 27, 2026, at 9:00 a.m. IST and conclude on September 29, 2026, at 5:00 p.m. IST. The cut-off date for determining voting rights is September 23, 2026. The AGM itself is scheduled for September 30, 2026. The company will utilize the e-voting services provided by National Securities Depository Limited (NSDL).

Ishita Drugs & Industries Ltd has announced that its 33rd Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 11:30 AM at "Manthan", Hotel Krsna Lila, Nr. Rexroth Bosch, Village lyava, Taluka Sanand, Sanand Viramgam Highway, Gujarat. The company will also close its Register of Members and Share Transfer Book from September 24, 2026, to September 30, 2026, inclusive, for the purpose of the AGM. The Integrated Annual Report and Notice of the AGM will be sent in due course.

Ishita Drugs & Industries Ltd announced that its Board of Directors met on August 8, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. The board also approved the re-appointment of Mrs. Abha Agrawal as a Non-Executive Non-Independent Director and accepted a revised remuneration proposal for Mr. Sumit Agrawal, the Chief Financial Officer. Additionally, the board discussed the ongoing upgradation project of the manufacturing facility, with approximately ₹435 lakh spent to date and capital contracts of about ₹565 lakh issued for utilities and equipment. The company is also in talks with banks to finance this project.

Ishita Drugs & Industries Ltd announced the re-appointment of Mrs. Abha Agrawal as a Non-Executive Non-Independent Director, following her attainment of 75 years of age. The company's Board of Directors also approved the Unaudited Financial Results for the quarter ended June 30, 2026. Additionally, the Board approved amendments to the notice for the 33rd Annual General Meeting and accepted revised remuneration for the CFO. The company is also progressing with its manufacturing facility upgradation project, with significant expenditure incurred and ongoing negotiations for financing.

Ishita Drugs & Industries Ltd announced the outcome of its Board meeting held on August 8, 2026. The Board approved the Unaudited Financial Results for the quarter ended June 30, 2026. Key decisions included the re-appointment of Mrs. Abha Agrawal as a Non-Executive Non-Independent Director, subject to shareholder approval. The Board also approved amendments to the notice for the 33rd Annual General Meeting and accepted a revised remuneration proposal for the CFO, Mr. Sumit Agrawal. Significant progress was reported on the manufacturing facility upgradation project, with approximately ₹435 lakh spent and capital contracts of ₹565 lakh issued for utilities and equipment. The company is also in discussions to raise funds for this project.

Ishita Drugs & Industries Ltd has announced that its Board of Directors will convene on August 8, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter ended June 30, 2026. Additionally, the meeting will address any other business with the chair's permission. In line with SEBI regulations, the trading window for designated persons will remain closed from July 1, 2026, until 48 hours after the announcement of these financial results.

Ishita Drugs & Industries Ltd has announced the closure of its trading window for designated persons. This closure will be effective from Wednesday, July 1, 2026, and will remain in effect for 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct.